Versican Plus BbPI IN nasal drops, lyophilisate and solvent for suspension for dogs
Versican Plus BbPI IN nasal drops, lyophilisate and solvent for suspension for dogs
Authorised
- Canine parainfluenza virus, strain CPiV-2-Bio 15, Live
- Bordetella bronchiseptica, strain MSLB 3096, Live
Product identification
Medicine name:
Versican Plus BbPI IN nasal drops, lyophilisate and solvent for suspension for dogs
Versican Plus BbPi IN
Active substance:
- Canine parainfluenza virus, strain CPiV-2-Bio 15, Live
- Bordetella bronchiseptica, strain MSLB 3096, Live
Target species:
-
Dog
Route of administration:
-
Nasal use
Product details
Active substance and strength:
-
Canine parainfluenza virus, strain CPiV-2-Bio 15, Live3.50log10 tissue culture infective dose 501.00Dose
-
Bordetella bronchiseptica, strain MSLB 3096, Live8.00log10 colony forming unit(s)1.00Dose
Pharmaceutical form:
-
Lyophilisate and solvent for oral suspension
Withdrawal period by route of administration:
-
Nasal use
-
Dog
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AF01
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Germany
Package description:
- (ID2): 1 Box with (10 Vial (Glass) with 1 Dose and 10 Vial (Glass) with 0.5 millilitre(s)) (10.0 Dose, 5.0 millilitre(s))
- (ID1): 1 Box with (5 Vial (Glass) with 1 Dose and 5 Vial (Glass) with 0.5 millilitre(s)) (5.0 Dose, 2.5 millilitre(s))
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
- Zoetis Deutschland GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
- Bioveta a.s.
Responsible authority:
- Paul-Ehrlich-Institut
Authorisation number:
- PEI.V.12002.01.1
Date of authorisation status change:
Reference member state:
-
Germany
Procedure number:
- DE/V/0288/001
Concerned member states:
-
Austria
-
Belgium
-
Croatia
-
Cyprus
-
Czechia
-
Estonia
-
France
-
Greece
-
Hungary
-
Ireland
-
Italy
-
Latvia
-
Lithuania
-
Luxembourg
-
Netherlands
-
Poland
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
English (PDF)
Download Published on: 18/09/2024
Updated on: 25/02/2025
German (PDF)
Published on: 18/09/2024
Updated on: 25/02/2025
Combined File of all Documents
This document does not exist in this language (English). You can find it
in another language below.
German (PDF)
Published on: 25/02/2025
2613944-paren-20200212.pdf
English (PDF)
Download Published on: 18/09/2024
How useful was this page?: